Basic Information
| LncRNA/CircRNA Name | RP11 |
| Synonyms | PRP31, SNRNP61, NY-BR-99 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Microarray, RNAi, other |
| Sample | HCC tissues and cell lines(SK-HEP1, SM7721, HepG2, and Huh7) |
| Expression Pattern | up-regulated |
| Function Description | A differentially expressed lncRNA-RP11, the most related to the EMT of liver cancer cells-RP11 was identified by abioinformatics method Overexpressing and silencing assays were used to verify the role of RP11 in cancer cell EMT. The levels of RP11- and EMT-related genes in liver cancer samples from 75 patients were detected by using qualitative polymerase chain reaction or immunohistochemistry. We identified 1334 pcRNAs and 1670 lncRNA with differential expression induced by ART. ART inhibits EMT, proliferation, migration, invasion, and adhesion of liver cancer cells. RP11 depresses the inhibitory effect of ART on cancer cell EMT. The level of RP11 is associated with cancer cell EMT and metastasis and survival rate of the patient. |
| Pubmed ID | 30335897 |
| Year | 2019 |
| Title | Dependence of Artesunate on Long Noncoding RNA-RP11 to Inhibit Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma |
External Links
| Links for RP11 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |